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Abstract 
A crucial issue in microRNA (miRNA) detection is the lack of sensitive method capable of detecting the 
low levels of miRNA in RNA samples. Herein, we present a sensitive and specific method for the 
electrocatalytic detection of miR-107 using gold-loaded nanoporous superparamagnetic iron oxide 
nanocubes (Au-NPFe 2 O 3 NC). The target miRNA was directly adsorbed onto the gold surfaces of Au-
NPFe 2 O 3 NC via gold-RNA affinity interaction. The electrocatalytic activity of Au-NPFe 2 O 3 NC was 
then used for the reduction of ruthenium hexaammine(III) chloride (RuHex, [Ru(NH 3 ) 6 ] 3+ ) bound with 
target miRNA. The catalytic signal was further amplified by using the ferri/ferrocyanide [Fe(CN) 6 ] 3-/4- 
system. These multiple signal enhancement steps enable our assay to achieve the detection limit of 100 
aM which is several orders of magnitudes better than most of the conventional miRNA sensors. The 
method was also successfully applied to detect miR-107 from cancer cell lines and a panel of tissue 
samples derived from patients with oesophageal squamous cell carcinoma with excellent reproducibility 
(% RSD = < 5%, for n = 3) and high specificity. The analytical accuracy of the method was validated with a 
standard RT-qPCR method. We believe that our method has the high translational potential for screening 
miRNAs in clinical samples. 
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A crucial issue in microRNA (miRNA) detection is the lack of sensitive method capable of 
detecting the low levels of miRNA in RNA samples. Herein, we present a sensitive and 
specific method for the electrocatalytic detection of miR-107 using gold-loaded nanoporous 
superparamagnetic iron oxide nanocubes (Au-NPFe2O3NC).  The target miRNA was directly 
adsorbed onto the gold surfaces of Au-NPFe2O3NC via gold-RNA affinity interaction. The 
electrocatalytic activity of Au-NPFe2O3NC was then used for the reduction of ruthenium 
hexaammine(III) chloride (RuHex, [Ru(NH3)6]
3+
) bound with target miRNA. The catalytic 
signal was further amplified by using the ferri/ferrocyanide [Fe(CN)6]
3-/4-
 system. These 
multiple signal enhancement steps enable our assay to achieve the detection limit of 100 aM 
which is several orders of magnitudes better than most of the conventional miRNA sensors. 
The method was also successfully applied to detect miR-107 from cancer cell lines and a 
panel of tissue samples derived from patients with oesophageal squamous cell carcinoma 
with excellent reproducibility (% RSD = <5%, for n = 3) and high specificity. The analytical 
accuracy of the method was validated with a standard RT-qPCR method. We believe that our 
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MicroRNAs (miRNAs) are short (approximately 19-23 nucleotides) and endogenous 
noncoding RNAs that control a range of cellular processes including post-transcriptional gene 
expression and epigenetic remodelling (Dong et al., 2013). The emerging functional insights 
of miRNAs and their promising role as the biomarker for various diseases including cancer 
have triggered extensive development of miRNA detection technologies (Dong et al., 2013; 
Hayes et al., 2014; Islam et al., 2017). Despite these developments, the miRNA detection 
technologies have yet to achieve their translation into routine clinical applications, partly due 
to the lack of sensitive and specific analysis methods (Islam et al., 2017). It is important to 
note that the abundance of miRNA in clinical samples is typically at the 0.2 fM to 20 pM 
level (Dong et al., 2013; Johnson and Mutharasan, 2014). Moreover, structure and size 
homology of closely-related non-target RNAs present in the clinical samples pose significant 
challenges in their specific detection (Labib et al., 2016).The detection method therefore 
needs to be highly sensitive as well as specific with negligible non-specific background 
response.  
A few nucleic acid detection methods; namely microarrays, RNA-sequencing (RNA-
seq) and real time quantitative polymerase chain reaction (RT-qPCR) have been developed 
for the investigation of RNA (Mestdagh et al., 2014). However, due to the size match of 
miRNA and standard PCR primers, most of these methods cannot efficiently amplify the 
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target miRNAs (Pritchard et al., 2012). To overcome this, enzymatic elongation of the 
template miRNA (e.g., polyadenylation) and specially designed primers (e.g., oligo dT or 
stem-loop primers) have been used. Additionally, RT-qPCR has the limitation for the 
absolute quantification of miRNAs since it analyses miRNA expression with an internal 
standard (Islam et al., 2017). Among other amplification-based strategies, the high 
throughput microarray and RNA-seq methods are best suited for discovery and validation of 
novel miRNA biomarkers rather than diagnostic applications. Moreover, all these methods 
largely depend on sophisticated and costly laboratory instrument, which is not suitable for the 
miRNA biomarker screening in resource-limited settings.  
In recent years, increasing interest in the simple, miniaturized and cost-effective 
analysis of biomarkers has led to the development of many electrochemical strategies which 
generally rely on capture probe-based hybridization or sandwich assay formats (Fang et al., 
2017; Labib and Berezovski, 2015). However, these electrochemical assays may not meet the 
requirement of ultrasensitive miRNA detection in clinical samples, mainly due to the lack of 
appropriate signal enhancement ability. It has been widely reported that one of the effective 
ways to increase the sensitivity of electrochemical assays is the use of nanomaterial-based 
signal amplification strategies. Nanomaterials have the inherent advantages of high catalytic 
properties, biomimetic activity, biocompatibility, excellent conductivity and high sample 
loading capacity (Dong et al., 2013; Xia et al., 2015). Therefore, nanomaterials have widely 
been used in electrochemical sensors as the tracers, catalysts and electronic conductors to 
improve the sensitivity of miRNA detection (Dong et al., 2013; Peng et al., 2014; Xia et al., 
2013). For example, Gao and Yang (2006) used isoniazid-capped OsO2 nanoparticles for 
labelling RNA molecules to electrocatalytically amplify the detection signal. Recently, 
composite nanomaterials, such as bimetallic hybrid nanomaterials (e.g., Fe2O3@Ag), have 
also been used for amplifying electrocatalytic signal in detecting miRNA (Pang et al., 2016).  
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Very recently, we designed and synthesized a new class of gold-loaded ferric oxide 
nanocubes (Au-NPFe2O3NC) (Yadav et al., 2017) that exhibit several functionalities. These 
includes (i)  superparamagnetic – the nanocubes are paramagnetic and thus highly suitable for 
magnetic isolation and separation; (ii) electrocatalyst – the nanocubes possess high 
electrocatalytic activity (Masud et al., 2017)
 
towards many common electroactive materials 
such as ruthenium hexaammine(III) chloride (RuHex, [Ru(NH3)6]
3+
), and (iii) enhanced 
loading capacity – the exposed gold surfaces of the highly porous Au-NPFe2O3NC can be 
used to adsorb large amount of target nucleotide sequences via DNA/RNA- gold affinity 
interaction (Islam et al., 2017b; Koo et al., 2016a, b; Koo et al., 2015; Sina et al., 2014a; Sina 
et al., 2014b).
 
The increasing demand for detecting the ultralow levels of miRNAs with 
electrochemical techniques has also resulted in the integration of more than one signal 
amplification step in a single assay platform (Fang et al., 2017; Liu et al., 2014). In particular, 
the nanoparticle-mediated electrocatalysis can be coupled with one or more electrocatalytic 
cycles to obtain enhanced sensitivity (Zhang et al., 2006). In such electrocatalytic assays, one 
redox molecule is first electrochemically oxidized or reduced at the electrode surface upon 
hybridization/intercalation with the target sequence (Zhang et al., 2007). This reaction is then 
coupled to another redox molecule that regenerates the oxidized or reduced species back to its 
original state. The resultant sharp increase in the electron flux produces an enhanced 
electrochemical signal. For example, Barton and Kelley groups have reported a series of 
studies to detect different DNA-based biomarkers where electroactive methylene blue (MB) 
or RuHex were coupled to ferri/ferrocyanide ([Fe(CN)6]
3-/4-
) to obtain the amplified 
electrocatalytic signal (Boon et al., 2000; Kelley et al., 1999; Lapierre et al., 2003). 
In this paper, leveraging the benefits of superparamagnetic, high eletrocatalytic 
activity and surface loading capacity of highly porous framework of Au-NPFe2O3NC and 
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portability of disposable screen-printed carbon electrode (SPCE), we develop an miRNA 
detection method which pushed the detection limit down to attomolar levels (LOD = 100 
aM). It has been reported that, conventional gold disk electrodes often exhibit excess 
background currents due to their high electrocalaytic properties and capacitive charges (Park 
et al., 2014). Moreover, due to multiple surface reactions on these conventional electrodes, 
tedious cleaning procedures are required for their full functionality. On the contrary, our 
assay uses single-use (i.e., disposable) and relatively inexpensive SPCE as a platform to load 
the magnetically bound nanocubes, which avoids this time-consuming cleaning procedure 
thereby reducing the assay time and simplifying the protocol. Moreover, SPCE is portable 
(three-electrode systems is printed on a plastic or ceramic substrates) and has minimal sample 
requirement which illustrates their potential scope towards the development of miniaturized 
analytical device suitable for on-site application.  In this assay, streptavidin-functionalised 
dyanabeads were first modified with a biotinylated capture probe. Then, they are dispersed in 
RNA sample population to isolate and purify the target miRNA. Afterwards, the isolated 
target miRNA was directly adsorbed on the Au-NPFe2O3NC (via RNA-gold affinity 
interaction) which was magnetically immobilized on a SPCE. The detection was then 
achieved by chronocoulometric (CC) charge measurement of surface bound cationic 
[Ru(NH3)6]
3+
 which was electrostatically attached with the anionic phosphate backbone of 
the adsorbed target miRNA. The signal was further amplified by coupling the reduction of 
[Ru(NH3)6]
3+
 with the [Fe(CN)6]
3-/4




system). We have 
selected miR-107 as a model target in this assay, which has diagnostic and prognostic roles in 
many cancers including oesophageal squamous cell carcinoma (ESCC) (Patnaik et al., 2010; 
Sharma et al., 2013).
 
The clinical applicability of the assay was successfully tested in a panel 
of eight tissue samples derived from patients with ESCC. The data were validated with a 




2. Experimental sections 
2.1. Isolation of Target miRNA  
ESCC cell lines (HKESC-1 and HKESC-4) were grown and maintained according to 
the previouly described procedures (Cheung et al., 2007; Hu et al., 2000). The RNA samples 
from four matched fresh ESCC and non-neoplastic tissues were used for this study (Haque et 
al., 2017).
 
Total RNA was extracted and purified from the cell lines and tissue samples 
according to manufacturer’s guidelines (Qiagen, Germany). Target miRNA was captured via 
dynabead-based miRNA separation procedures with a slight modification of our previous 
report (Koo et al., 2016b).
 
Briefly, target miRNA were
 
hybridized onto complementary 
capture probes functionalized
 
magnetic beads (The list oligonucleotide sequences are 
provided in Table S1). Then, hybridized targets were
 
magnetically purified, heat-released, 
and resuspended in RNase-free water. (See supplementary materials for more details) 
 
2.2. Electrochemical Detection of miRNA 
In this study, we utilized Au-NPFe2O3NC to modify SPCE (SEM images of the bare 
and modified SPCE are provided in Fig. S1, where the bio-favourable physicochemical 
properties of AuNPs (i.e. affinity interaction of DNA/RNA with gold) was exploited to 
capture target miRNAs. Briefly, SPCE was rinsed with an excess amount of Milli-Q water 
before the adsorption of miRNA. To attach Au-NPFe2O3NC to the SPCE surface, the 
electrode was placed on a permanent magnet and 4.0 μg of Au-NPFe2O3NC was put and 
incubated onto the electrode surface for 45 min. The electrode was then washed with 10 mM  
PBS to remove any unattached or loosely attached particles from the electrode surface. The 
effective areas of SPCE was determined by using the Randles -Sevcik equation (See Eqn. S1 
in supplementary materials) as shown before (Shiddiky et al., 2010; Shiddiky et al., 2009). 
Fig. S2 shows the typical cyclic voltammogram of bare and modified electrodes. Using CC, 
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the amount of miRNA adsorbed onto the Au-NPFe2O3NC/SPCE surface was calculated from 
the number of cationic RuHex electrostatically bound with the surface-attached anionic 
phosphate backbone of miRNA following the integrated Cottrell Eqn (Steel et al., 1998).(See 
supplementary materials for detailed experimental) 
 
3. Results and discussion 
3.1. Detection Principle 
The principle of our assay is schematically illustrated in Fig. 1.  The assay is comprised of 
three main steps including (i) magnetic separation and purification of target miR-107, (ii) 





 system based electrocatalytic signal amplification. Briefly, total 
RNA extracted from de-identified ESCC tissue were initially incubated with the miR-107 
specific biotinylated capture probe. Upon hybridization of the capture probe with miR-107, 
streptavidin-labelled dynabeads were dispersed into the reaction mixture which attached with 
the biotinylated capture probe-target duplex. In this assay, commercially available 
streptavidin-coated dynabeads are functionalised with biotinylated capture probe and used for 
the magnetic isolation and purification of target miRNAs from the RNA sample pool. The 
complex was then magnetically isolated using dynabead-based standard protocol. After 
heating at 95 oC, the released (target) miRNA was isolated by another magnetic separation 
step (See Experimental Section for details) and directly adsorbed onto the Au-NPFe2O3NC-
modified screen-printed carbon electrode (SPCE/Au-NPFe2O3NC). The direct adsorption of 
RNA on the gold surface was facilitated by RNA-gold affinity interaction phenomenon which 
was demonstrated earlier (Islam et al., 2017b; Koo et al., 2016a, b). The target miR-107 were 





where positively charged [Ru(NH3)6]
3+ 
binds to the anionic phosphate backbone 
of miR-107 adsorbed on the SPCE/Au-NPFe2O3NC surfaces.  
To further amplify the electrochemical signal, [Ru(NH3)6]
3+ 
system was coupled to 
[Fe(CN)6]
3-
 where the electrocatalytic reduction of [Ru(NH3)6]
3+ 
further reduces the solution-
phase [Fe(CN)6]
3-
. Because  [Fe(CN)6]
3- 
in the solution (i.e., diffusion layer) is relatively 
stronger oxidant, it oxidized  [Ru(NH3)6]
2+ 
for the regeneration of [Ru(NH3)6]
3+
  (i.e., 
initiation of the electrocatalytic cycle ). Thus, the electrocatalytic cycle reported here follows 
an electron transfer kinetic-based mechanism which can be described by the following Eqn.1 
and 2 (Zhang et al., 2007).  
 




NHRueNHRu  … … … … (1) 







CNFeNHRuCNFeNHRu … … … …  (2) 
 





 system after miRNA binding onto the surface of SPCE/Au-
NPFe2O3NC should have a clear correlation with the concentration of target miRNA. 
 
3.2. Electrocatalytic Activity of Au-NPFe2O3NC and Signal Enhancement 
 To check the effect of the composition of nanomaterials on the electrocatalytic 
activity and signal enhancement of our assay, we modified SPCE with NPFe2O3NC 
(nanoporous iron oxide nanocubes without AuNPs) and Au-NPFe2O3NC and compared the 
assay performance for detecting miR-107 from 10 pM of synthetic RNA sample. As can be 
seen in Fig. 2 (left bar) and Fig. S3 (left bar, in supplementary materials), the total charge 
density (total charge Q represents the Faradaic and non-Faradaic charges) obtained with the 
10 
 
SPCE/NPFe2O3NC and SPCE/bare electrodes were found to be 4.5 and 1.8 μCcm
-2 
respectively. The low level response for the SPCE/bare electrode could be responsible for the 
non-Faradaic component of the CC charge at the bare electrode. A slight increase of the CC 
charge (1.8 versus 4.5 μCcm
-2
) at the SPCE/NPFe2O3NC-modified electrode could be related 
to both the Faradaic and non-Faradaic component of the charges. This may be related to the 
fact that a low amount of redox active [Ru(NH3)6]
3+
 could be adsorbed on the NPFe2O3NC, 
leading to the Faradaic component of the charges. When the electrode was modified with Au-
NPFe2O3NC (i.e., SPCE/Au-NPFe2O3NC), the total charge density significantly increased for 
the [Ru(NH3)6]
3+
 system compared to that obtained with the SPCE/bare (~11-fold higher, 20 
versus 1.8 μCcm
-2
) or SPCE/NPFe2O3NC-modified electrodes (~4.5 times higher, 20 versus 
4.5 μCcm
-2
). The enhancement of the charge response for the SPCE/Au-NPFe2O3NC 
electrode could be explained by considering these two facts (i) large surface loading capacity 
of highly porous framework of Au-NPFe2O3NC and (ii) the intrinsic electrocatalytic activity 




The target miR-107 was directly 
adsorbed onto the exposed gold surfaces of the Au-NPFe2O3NC via RNA-gold affinity 
interaction, which follows conventional physisorption and chemisorption mechanism. The 
surface-bound miR-107 (negatively charged) binds with [Ru(NH3)6]
3+ 
and thereby generating 
a higher CC charge (due to the larger contribution from Faradaic component). Recently, we 
have demonstrated the electrocatalytic activity of Au-NPFe2O3NC toward the reduction of 
[Ru(NH3)6]
3+
,  where the Au-NPFe2O3NC-modified glassy carbon electrode (GCE) offered 
significantly enhanced cathodic (ipc), and anodic (ipa) peak currents for the [Ru(NH3)6]
3+/2+
 
system  when compared to that of the unmodified-GCE electrode (Figs. S4 and S5 in the 
supplementary materials). We have also shown that the electrocatalytic activity of Au-
NPFe2O3NC follows typical Michaelis-Menten behaviour as well as Lineweaver-Burk Model 
for electrocatalysis
 
(Masud et al., 2017). As our assay design requires both gold-RNA affinity 
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interaction for adsorbing target miRNA and electrocatalysis for signal enhancement, we 
synthesised highly porous Fe2O3, which favors the controlled-loading of 2% AuNPs to 
achieve Au-NPFe2O3NC.  
To further enhance the catalytic signal, we coupled [Fe(CN)6]
3-/4- 
system with the 
[Ru(NH3)6]
3+/4+
. As can be seen in Fig. 2 (right bar), a 4-fold increase in the CC response was 
obtained compared to that of the [Ru(NH3)6]
3+
 system (20 versus 82 μCcm
-2
) at the 
SPCE/Au-NPFe2O3NC electrode. This response is also 18 times higher compared to that of 
the SPCE/NPFe2O3NC- modified electrode (82 versus 4.5 μCcm
-2
), demonstrating the 
catalytic signal amplification for detecting miR-107 at the SPCE/Au-NPFe2O3NC electrode. 
We assume that apart from the large surface loading capacity and electrocatalytic activity of  




system), a few other added features 
also attributed to this sensitivity, such as (i) SPCE/Au-NPFe2O3NC/RNA-bound surface 
confined [Ru(NH3)6]
3+
 could generate  more intense CC signal  compared to voltammetry 
where the electrostatic interaction is free of any duplex intercalation and (ii) the double layer 
charge and charge derived from the surface confined target miRNA can easily be 
differentiated from the redox charges in diffusion layers allowing more sensitive charge 
measurements.   
 
3.3. Assay Specificity 
To check the assay functionality and specificity, we performed our assay in the 
absence and presence of complementary or non-complementary target miRNAs. In the 
absence of target miR-107 (i.e., SPCE/Au-NPFe2O3NC without miR-107, control), the total 




 system was significantly higher than that of 
the SPCE/bare electrode (4.5 vs 18.1 μCcm
-2
) (Fig. S3 vs Fig. 3).  This charge density for the 
[Ru(NH3)6]
3+
 system was 7.5 μCcm
-2 
(Fig. S3, supplementary materials). This is probably due 
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to the presence of a low amount of [Ru(NH3)6]
3+
 on the control electrode via nonspecific 
adsorption. In the case of the two non-complementary synthetic miRNAs (miR-21 and miR-
338-3p), as expected, using the same starting concentration (10 pM), the total charge 
densities obtained for the miR-21 and miR- 338-3p was found to be 16.1 and 17.3 μCcm
-2 
respectively (Fig. 3). These values for the [Ru(NH3)6]
3+
 system was 6.0 and 7.3 μCcm
-2 
respectively (Fig. S3). Notably, the CC responses obtained with the non-complementary 




 system were similar to that obtained from the control 
response. A similar trend was obtained for the [Ru(NH3)6]
3+
 system (Fig. S3, supplementary 
materials). This shows that the assay is not affected by the nonspecific response from similar 
size miRNAs. However, when compared to the total charge derived from non-specific targets 
and controls, the CC response from the target miR-107 was increased about 4-fold (82 μC 
cm
-2
) (Fig. 3). This enhancement was about 2.5-fold for the [Ru(NH3)6]
3+
 system (Fig. S3). 
These results clearly demonstrate the high specificity of our assay. The specificity of our 
developed assay is also comparable to several recently reported high-performance biosensors 
(Koo et al., 2016b; Liao et al., 2017; Wang et al., 2014).  
 
3.4. Assay Sensitivity 
 To evaluate the assay sensitivity, a series of designated concentration of synthetic 
miR-107 ranging from 100 aM to 1.0 nM were detected by our assay. As shown in Fig. 4, the 




 system increased with the increasing 
concentration of the target miRNA. This can be explained by the fact that, an increasing 
amount of miR-107 on the SPCE/Au-NPFe2O3NC electrode surface will have more anionic 
phosphate groups which in turn binds with more cationic [Ru(NH3)6]
3+
. Thus more 
[Ru(NH3)6]
3+ 
will be electrocatalytically reduced to further catalyse the reduction of 
[Fe(CN)6]
3-
 in the diffusion layer, thereby resulting enhanced CC response. The linear 
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regression equation of the assay was estimated to be y (charge density, μCcm
-2
) = 10.85 
(amount of miR-107) + 3.1638, with a correlation coefficient (R
2
) of 0.9984. The limit of 
detection (LOD) was estimated to be 100 aM and the response is clearly distinguishable from 
that of control and bare electrodes. It is important to mention that without the use of catalytic 
cycle step (only with the [Ru(NH3)6]
3+
system), we achieved a detection limit of 100 fM (100 





 system (see Fig. S6).  
 The LOD of our method is superior or comparable with those of existing miRNA 
electrochemical assays (Koo et al., 2016b; Pang et al., 2016; Yao et al., 2014).
 
For example, 
the LOD of our method is approximately 1,000 times better than a recent choronoloumetric 
detection method reported by Yao et al. (2014). In addition to the superior sensitivity, our 
assay is relatively inexpensive (enzyme free, low-cost synthesis of Au-NPFe2O3NC) and 
simple (via adopting direct RNA adsorption and electrocatalytic signal amplification) 
whereas the method developed by Yao et al.
 
 relies on the enzyme based rolling-circle 
amplification process. Our approach has also obtained 100-folds better sensitivity than the 
voltammetric method reported by Koo et al (2017b).  Moreover, while the voltammetric 
method requires the target (RNA) modification (i.e., polyadenylation) using Poly-A enzyme, 
our approach offers relatively simple (avoids pre-modification of target RNAs) and 
inexpensive (avoids costly enzymes) assay platform. A comparison of the LOD of our 
method with that of several other existing electrochemical methods reported in the last five 
years has been provided in Table S2 of supplementary materials.    
 
3.5. Analysis of miR-107 in Patient Derived Cell Lines and Tissues 
To determine whether our assay could be applied to real biological samples, we tested 
our method in total RNA sample extracted from human ESCC cell lines (HKESC-1 and 
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HKESC-4) and one non-neoplastic oesophageal mucosa sample (as a control).  As shown in 
Fig. 5A and B, the corresponding bar diagram for QRNA and typical CC curve demonstrated 
that the CC response obtained with cancer cells from HKESC-1 and HKESC-4 was 
significantly higher than that of normal (70 and 54 vs 19 μCcm
-2
) suggesting the 
overexpression of miR-107. We then validated our assay performance in cancer cells with a 
RT-qPCR. As seen in Fig. 5C, the expression fold change data of a RT-qPCR strongly 
supports our findings (Fig. 5C vs Fig. 5A). 
To further demonstrate the potential clinical applications, we extended our method to 
analyse miR-107 from the total RNA extracted from cancer tissues with their matched non-
cancer tissues from 4 patients. As indicated in Fig. 6A and B, all eight total RNA samples 
(including non-cancer tissue RNA; N1-N4 and cancer tissue RNA; P1-P4) showed different 
levels of miR-107 expression. For example, CC charge density obtained for P1 (T) was 
almost doubled when compared to the matched non-cancer P1(N) (67 vs 24 μCcm
-2
). A 
similar trend was obtained for the other patients samples where CC response derived from 
cancer samples (P2-P4) had significantly higher charge densities compared to the non-
neoplastic counterparts (N2-N4), suggesting an upregulation of miR-107 expression in the 
ESCC tissue samples.  We then validated our assay performance with a standard RT-qPCR 
method which was in excellent agreement with our findings (Fig. 6A vs 6C). The 
reproducibility of our assay (relative standard deviation, % RSD = <5%, for n=3) in 
analysing clinical sample is also in acceptable range, which shows better (Bettazzi et al., 
2013) or comparable (Bartosik et al., 2014; Hong et al., 2013; Koo et al., 2016b; Miao et al., 
2016) reproducibility when compared to the recently reported miRNA electrochemical 
sensors. The level of the reproducibility, sensitivity and selectivity of our assay in analysing 
patient sample as well as the validation with RT-qPCR analysis indicates the enormous 
potential of our detection method for screening clinically relevant miRNAs. Also, this 
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approach has future implications in profiling gene expressions and molecular pathways in 
patients with cancer and other chronic diseases.  
 
3.6. Advantages of the Assay 
The assay offers an important progress towards the ultrasensitive detection of miRNA. First, 
utilization of highly porous structure of Au-NPFe2O3NC significantly enhances the capture 
efficiency via loading vast amounts of RNA on the gold surfaces. Additionally, it offers the 
direct and fast electron transfer between the target and electrode surface attributing the high 
sensitivity of the assay. Second, unlike the traditional heterogeneous hybridization-based 
detection, our assay exploits magnetic nanoparticle-based intimate mixing, separation and 
purification of miRNA which reduce the matrix effects of the biological samples. Thus, the 
method is less susceptible to non-specific detection. Third, the direct adsorption of target 
miRNA on an Au-NPFe2O3NC-modified electrode rather than the conventional RNA 
biosensing approach of using recognition and transduction layers, substantially simplifies the 
detection method by avoiding the complex chemistries underlying each step of the sensor 
fabrication. Fourth, RuHex bound electrostatically with the target, thereby avoiding the need 
of expensive electrochemical tags or labelling. Finally, electrochemical detection can 
complement with the miniaturized and multiplexed analysis in non-laboratory settings with 
high translational potential.  
 
4. Conclusions 
In conclusion, we have developed a sensitive electrochemical method for detecting small 
non-coding RNA (miRNAs) using multiple electrocatalytic signal amplification steps. 
Magnetically separated and purified target miRNA was directly adsorbed on novel Au-
NPFe2O3NC nanocomposites with high electrocatalytic activity. Further chronocoulometric 
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charge interrogation of surface-bound RuHex (via interaction between [Ru(NH3)6]
3+ 
and 
miR-107 adsorbed onto the SPCE/Au-NPFe2O3NC) coupled with the [Fe(CN)6]
3-/4-
 system 
result in a significant signal enhancement via electrocatalytic cycle. The assay enabled the 
ultra-low level of limit of detection of 100 aM and showed high reproducibility (% RSD 
=<5%, for n = 3) and specificity towards detecting a known oncogenic miRNA, miR-107, in 
cell lines and tissue samples collected from patients with ESCC. This application of our assay 
on both in vitro and in vivo based clinical samples suggests the future use of screening any 
biomarkers including miRNAs (depending on the selection of specific capture probe). 
Considering the versatility of our assay, we believe that with further optimisation, this new 
strategy based on nanocomposite and electrocatalytic cycle can potentially be applicable for 
the determination of a wide variety of clinically relevant DNA or RNA biomarkers for other 
human cancers and chronic diseases. 
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Figure captions  
Fig. 1. Schematic overview of the assay. Target miRNA was first magnetically isolated and 
purified from the RNA sample pool and adsorbed directly on the Au-NPFe2O3NC which was 
magnetically held on the SPCE electrode. The [Ru(NH3)6]
3+ 
was electrostatically attached 
with the surface bound negatively charged miRNAs.  The detection was achieved by the 




 electrocatalytic cycle.  
 
Fig. 2. Charge density obtained for the 10 pM synthetic miR-107 at the SPCE/NPFe2O3NC, 
SPCE/Au-NPFe2O3NC (with and without electrocatalytic cycle) electrodes. Total charge, Q = 
Faradaic + non-Faradaic charges of the system. Inset, corresponding CC curves (Q vs t
1/2
). 
Each data point represents the average of three independent trials, and error bars represent the 
standard deviation of measurements (% RSD = <5%, for n = 3). 
 
Fig. 3. Assay specificity. Charge density obtained for the synthetic miR-107 at designated 




 electrocatalytic cycle. Left bar 
represents the charge density obtained at the bare SPCE after adsorbing 10 pM of target miR-
107. Control and Target-miRNA bars represent the charge density obtained at SPCE/Au-
NPFe2O3NC electrode before and after adsorbing 10 pM of target miR-107. miR-21 and miR-
338-3p bars represent the charge density obtained at SPCE/Au-NPFe2O3NC electrode after 
adsorbing 10 pM of non-complimentary miR-21 and miR-338-3p targets respectively. Inset, 
22 
 
corresponding CC curves (Q vs. t
1/2
). Each data point represents the average of three 
independent trials, and error bars represent the standard deviation of measurements (% RSD 
= <5%, for n = 3). 
Fig. 4. Assay sensitivity. (A) Typical CC curves (Q vs. t
1/2
) for the (b-i); 100 aM-1.0 nM of 
miR-107. Curves a is for the charge density obtained at SPCE/Au-NPFe2O3NC electrode 
before adsorbing target miR-107. (B) QRNA-concentration profile for the range of 100 aM to 
1.0 nM miR-107. Inset, corresponding calibration plot. The concentration of RuHex and 
ferricyanide is 50 μM and 4.0 mM respectively. Each data point represents the average of 
three independent trials, and error bars represent the standard deviation of measurements (% 
RSD = <5%, for n = 3). 
 
Fig. 5. Analysis of cell lines. (A) Corresponding bar diagram for QRNA obtained with 
HKESC-1 and HKESC-4 cancer cell line. (B) Typical CC curves (Q vs. t
1/2
) obtained with 
cell line samples. (C) RT-qPCR derived miR-107 expression profile (fold-change data) in cell 
lines. Each data point represents the average of three independent trials, and error bars 
represent the standard deviation of measurements (% RSD = <5%, for n = 3). 
 
Fig. 6. Analysis of patient samples. (A) Corresponding QRNA obtained for four ESCC 
patients (P1-P4) (four tumor samples with matched non-cancer samples, T-N).  (B) Typical 
CC curves (Q vs. t
1/2
) obtained with patients’ samples (C) RT-qPCR derived miR-107 
expression profile (fold-change data) in patient samples. Each data point represents the 
average of three independent trials, and error bars represent the standard deviation of 
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